MIRXES partners with XTALPI to build an integrated diagnosis and treatment platform

MIRXES-B (02629.HK) announced that it has signed a memorandum of understanding with XTALPI, under which both parties agree to integrate their core strengths in genomics technology and disease databases centered on the Asian population with XTALPI's leading AI+ robotics drug discovery and research platform. The collaboration aims to establish an AI-enabled, innovative "integrated diagnosis and treatment" research and industrialization platform focused on the early detection and intervention of high-incidence cancers in Asia, particularly gastrointestinal cancers, combining diagnosis and treatment to develop early diagnosis and treatment solutions